Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Skin

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 1 · 12.5%High 4 · 50%

Overall survival† · people with cutaneous melanoma

Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.94 [0.84, 1.06]
1317 participants
High

Overall survival† · people with cutaneous melanoma

Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.99 [0.85, 1.16]
594 participants
High

Overall survival† · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.6 [0.45, 0.81]
324 participants
Moderate

Overall survival† · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.81 [0.65, 1.01]
1157 participants
Low

Overall survival (OS) · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Overall survival† · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.42 [0.37, 0.48]
418 participants
High

Overall survival† · people with cutaneous melanoma

BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.4 [0.28, 0.57]
925 participants
High

Overall survival† · people with cutaneous melanoma

MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.85 [0.58, 1.25]
496 participants
Low